1. Home
  2. ROMA vs SLGL Comparison

ROMA vs SLGL Comparison

Compare ROMA & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$5.40

Market Cap

134.6M

Sector

Finance

ML Signal

HOLD

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

N/A

Current Price

$83.97

Market Cap

247.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ROMA
SLGL
Founded
2018
1997
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.6M
247.1M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
ROMA
SLGL
Price
$5.40
$83.97
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$110.00
AVG Volume (30 Days)
496.9K
11.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.71
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.40
52 Week High
$8.88
$97.97

Technical Indicators

Market Signals
Indicator
ROMA
SLGL
Relative Strength Index (RSI) 77.84 52.34
Support Level $2.05 $32.56
Resistance Level $8.88 $97.97
Average True Range (ATR) 0.86 11.37
MACD 0.36 -1.20
Stochastic Oscillator 53.75 44.14

Price Performance

Historical Comparison
ROMA
SLGL

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Share on Social Networks: